Phase 3 Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are having coronary artery bypass graft (CABG) surgery, with or without a heart-lung bypass machine, and with or without other heart procedures such as valve replacement.
- People whose heart surgery will not fully restore blood flow to all areas of the heart, based on physical or functional assessment.
- People who have given their written agreement to take part in the trial.
Who may not be able to join:
- People who had a heart attack or serious chest pain event within the 12 months before their surgery.
- People who are already taking two blood-thinning medications together at the time they are admitted to hospital.
- People for whom an additional planned procedure is already scheduled to complete the restoration of blood flow to the heart (for example, a combined surgical and non-surgical approach).
- People who are unable to take aspirin (acetylsalicylic acid) or ticagrelor, or who have had a bad reaction to either medication.
- People who have an irregular heart rhythm called atrial fibrillation before their surgery.
- People who may have difficulty following the trial's instructions or treatment schedule.
- People who are pregnant or planning to become pregnant.
- People who have previously experienced bleeding in the stomach or digestive tract.
- People with significantly reduced kidney function (confirm with trial site for specific measurement details).
- People with long-term liver disease.
- People with severe heart failure at the time they are admitted to hospital.
- People with a currently active cancer diagnosis.
- People with a history of alcohol misuse.
- People with any other health condition that the trial site determines is not compatible with the trial treatment.
People already enrolled may be removed from the trial if:
- They develop an irregular heart rhythm (atrial fibrillation) after surgery that requires blood-thinning treatment.
- They experience a bleeding event after surgery, such as a bleeding stroke or digestive tract bleeding.
- A reason arises after surgery that means aspirin or ticagrelor can no longer be safely used.
- A surgical situation arises that requires the use of two blood-thinning medications, making the trial treatment unsuitable.
- The participant chooses to withdraw from the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Massimo Chello, MD, Università Campus Bio-Medico di Roma, Rome, Italy
Phone: +393337014743
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cardiac-related mortality
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.